Table 1 Characteristics of the study population.
From: Epidemiology and risk factors for Staphylococcus aureuscolonization in children in the post-PCV7 era
|  | Total N = 1,968) | 16 communities swabbed in 2003–04 (N = 994) | 8 communities swabbed in 2006–07 (N = 974) | |
|---|---|---|---|---|
|  |  | 8 communities swabbed in 2003–04 only (N = 406) | 8 communities swabbed in both seasons (N = 588) | 8 communities swabbed in both seasons (N = 974) |
Age group (N = 1,968) | Â | Â | Â | Â |
   3–<6 months | 131 (6.7%) | 25 (6.2%) | 30 (5.1%) | 76 (7.8%) |
   6–<12 months | 299 (15.2%) | 53 (13.1%) | 67 (11.4%) | 179 (18.4%) |
   1–<2 years | 477 (24.2%) | 100 (24.6%) | 129 (21.9%) | 248 (25.5%) |
   2–<3 years | 274 (13.9%) | 61 (15.0%) | 82 (14.0%) | 131 (13.5%) |
   3–<4 years | 237 (12.0%) | 57 (14.0%) | 84 (14.3%) | 96 (9.9%) |
   4–<5 years | 231 (11.7%) | 50 (12.3%) | 79 (13.4%) | 102 (10.5%) |
   5–<7 years | 319 (16.2%) | 60 (14.8%) | 117 (19.9%) | 142 (14.6%) |
Female (N = 1,968) | 981 (49.9%) | 216 (53.2%) | 308 (52.4%) | 457 (46.9%) |
Race/ethnicity (N = 1,872) | Â | Â | Â | Â |
   White non-Hispanic | 1,565 (83.6%) | 341 (83.9%) | 463 (84.0%)20 (3.6%) | 761 (82.4%) |
   Black non-Hispanic | 86 (4.6%) | 15 (3.8%) | 20 (3.6%) | 51 (5.5%) |
   Hispanic | 122 (6.5%) | 23 (5.8%) | 28 (5.1%) | 71 (7.7%) |
   Other | 99 (5.3%) | 18 (4.5%) | 40 (7.3%) | 41 (4.4%) |
Median household income in community (N = 1,869)* | Â | Â | Â | Â |
   <40,000 | 373 (20.0%) | 125 (31.8%) | 104 (18.4%) | 144 (15.8%) |
   40,000–<55,000 | 620 (33.2%) | 122 (31.0%) | 191 (33.9%) | 307 (33.7%) |
   55,000–<70,000 | 447 (23.9%) | 85 (21.6%) | 135 (23.9%) | 227 (24.9%) |
   ≥70,000 | 429 (23.0%) | 61 (15.5%) | 134 (23.8%) | 234 (26.7%) |
% community members with <high school educational level (N = 1,869)* | Â | Â | Â | Â |
   <5% | 297 (15.9%) | 57 (14.5%) | 79 (14.0%) | 161 (17.7%) |
   5–<10% | 387 (20.7%) | 95 (24.2%) | 111 (19.7%) | 181 (19.9%) |
   10–<15% | 485 (26.0%) | 66 (16.8%) | 164 (29.1%) | 255 (28.0%) |
   ≥15% | 700 (37.5%) | 175 (44.5%) | 210 (37.2%) | 315 (34.5%) |
Ever breastfed (N = 1,900) | 1,291 (68.0%) | 237 (59.4%) | 400 (69.8%) | 654 (70.5%) |
Childcare or school for ≥4 hours (N = 1,857) | 941 (50.7%) | 184 (46.8%) | 296 (53.9%) | 461 (50.4%) |
Smokers in home (N = 1,784) | 355 (19.9%) | 97 (25.5%) | 87 (16.1%) | 171 (19.9%) |
Family member works in hospital or LTCF (N = 1,888) | 328 (17.4%) | 66 (16.7%) | 98 (17.5%) | 164 (17.6%) |
Antibiotics in past 2 months (N = 1,945) | Â | Â | Â | Â |
   Amoxicillin-clavulanate/cephalosporins/mupirocin/TMP-SMX | 212 (10.9%) | 42 (10.8%) | 61 (10.5%) | 109 (11.2%) |
   Clindamycin/macrolides | 82 (4.2%) | 22 (5.7%) | 24 (4.1%) | 36 (3.7%) |
   Amoxicillin/penicillin | 332 (17.1%) | 74 (19.0%) | 86 (14.8%) | 172 (17.7%) |
   None | 1,319 (67.8%) | 251 (64.5%) | 411 (70.6%) | 657 (67.5%) |
Antibiotics in past 6 months for skin infection (N = 1,950) | 29 (1.5%) | 0 (0%) | 1 (0.2%) | 28 (2.9%) |
History of chronic illness | Â | Â | Â | Â |
   Asthma/RAD (N = 1,950) | 199 (10.2%) | 27 (6.9%) | 80 (13.7%) | 92 (9.5%) |
   Skin condition†(N = 974) | 47 (4.8%) | - | - | 47 (4.8%) |
Diagnosis on day of visit (N = 1,950) | Â | Â | Â | Â |
   Asthma/RAD | 73 (3.7%) | 18 (4.6%) | 19 (3.3%) | 36 (3.7%) |
   Rash | 65 (3.3%) | 9 (2.3%) | 12 (2.1%) | 44 (4.5%) |
   Otitis media | 258 (13.2%) | 30 (7.7%) | 61 (10.5%) | 167 (17.2%) |
   Respiratory tract infection | 461 (23.6%) | 76 (19.4%) | 95 (16.3%) | 290 (29.8%) |
   Skin/soft tissue infection | 14 (0.7%) | 0 (0%) | 1 (0.2%) | 13 (1.3%) |
   Allergic rhinitis/seasonal allergies | 13 (0.7%) | 3 (0.8%) | 7 (1.2%) | 3 (0.3%) |
Colonization with Streptococcus pneumoniae (N = 1,964) | 524 (26.7%) | 91 (22.4%) | 141 (24.0%) | 292 (30.1%) |
Pneumococcal vaccination** (N = 1,950) | Â | Â | Â | Â |
   0 doses | 209 (10.7%) | 76 (19.4%) | 113 (19.4%) | 20 (2.1%) |
   1 dose | 170 (8.7%) | 40 (2.1%) | 61 (3.1%) | 69 (7.1%) |
   2 doses | 194 (10.0%) | 38 (9.7%) | 82 (14.0%) | 74 (7.6%) |
   3 doses | 1377 (70.6%) | 238 (60.7%) | 328 (56.2%) | 811 (83.3%) |
Influenza vaccination prior to visit††(N = 1,950) | 467 (24.0%) | 65 (16.6%) | 45 (7.7%) | 357 (36.7%) |